Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 274

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Circulating Transforming Growth Factor-β in Marfan Syndrome

Open access
Matt, Peter, Schoenhoff, Florian, Habashi, Jennifer, Holm, Tammy, Van Erp, Christel, Loch, David, Carlson, Olga D., Griswold, Benjamin F., Fu, Qin, De Backer, Julie, Loeys, Bart, Huso, David L., McDonnell, Nazli B., Van Eyk, Jennifer E., Dietz, Harry C., the GenTAC Consortium·2009·Circulation

Abstract

Background— Marfan syndrome (MFS) is caused by mutations in the fibrillin-1 gene and dysregulation of transforming growth factor-β (TGF-β). Recent evidence suggests that losartan, an angiotensin II type 1 blocker that blunts TGF-β activation, may be an effective treatment for MFS. We hypothesized that dysregulation of TGF-β might be mirrored in circulating TGF-β concentrations. Methods and Results— Serum obtained from MFS mutant mice ( Fbn1 C1039G /+ ) treated with losartan was analyzed for circulating TGF-β1 concentrations and compared with those from placebo-treated and wild-type mice. Aortic root size was measured by echocardiography. Data were validated in patients with MFS and healthy individuals. In mice, circulating total TGF-β1 concentrations increased with age and were elevated in older untreated Fbn1 C1039G /+ mice compared with wild-type mice ( P =0.01; n=16; mean±SEM, 115±8 ng/mL versus n=17; mean±SEM, 92±4 ng/mL). Losartan-treated Fbn1 C1039G /+ mice had lower total TGF-β1 concentrations compared with age-matched Fbn1 C1039G /+ mice treated with placebo ( P =0.01; n=18; 90±5 ng/mL), and circulating total TGF-β1 levels were indistinguishable from those of age-matched wild-type mice ( P =0.8). Correlation was observed between circulating TGF-β1 levels and aortic root diameters in Fbn1 C1039G /+ and wild-type mice ( P =0.002). In humans, circulating total TGF-β1 concentrations were elevated in patients with MFS compared with control individuals ( P <0.0001; n=53; 15±1.7 ng/mL versus n=74; 2.5±0.4 ng/mL). MFS patients treated with losartan (n=55) or β-blocker (n=80) showed significantly lower total TGF-β1 concentrations compared with untreated MFS patients ( P ≤0.05). Conclusions— Circulating TGF-β1 concentrations are elevated in MFS and decrease after administration of losartan, β-blocker therapy, or both and therefore might serve as a prognostic and therapeutic marker in MFS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.108.841981

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 274

Metadata

Authors
Matt, P., Schoenhoff, F., Habashi, J., Holm, T., Van Erp, C., Loch, D., Carlson, O. D., Griswold, B. F., Fu, Q., De Backer, J., Loeys, B., Huso, D. L., McDonnell, N. B., Van Eyk, J. E., Dietz, H. C., & the GenTAC Consortium
Venue
Circulation
Published
2009-08-11
Volume
120
Issue
6
Pages
526-532
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2018492695
Cited by
274
References
18
FWCI
10.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating Transforming Growth Factor-β in Marfan Syndrome. https://app.cochat.ai/papers/10.1161/circulationaha.108.841981
The paper
Matt, P., Schoenhoff, F., Habashi, J., Holm, T., Van Erp, C., Loch, D., Carlson, O. D., Griswold, B. F., Fu, Q., De Backer, J., Loeys, B., Huso, D. L., McDonnell, N. B., Van Eyk, J. E., Dietz, H. C., & the GenTAC Consortium. (2009). Circulating Transforming Growth Factor-β in Marfan Syndrome. Circulation. https://doi.org/10.1161/circulationaha.108.841981

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.